Revised code to increase investor confidence: promote it on your website


Thursday, 05 December, 2013

Biotechnology companies are urged to display their adherence to the ‘Code of Best Practice for Reporting by Life Science Companies’ on the company website - either on the front page or on the investor relations landing page.

The code has recently been revised and updated in consultation with the ASX and industry experts. An online endorsement ‘button’ for the use of companies that have implemented the code is available free of charge to indicate to investors that the company seeks to disclose according to best practice in accordance with the code, thus giving investors assurance in the life science business.

The code aims to support the directors and management of Australian ASX-listed life science companies to adopt international best practice in reporting events to investors. It also seeks to provide investors with a level of confidence through providing guidance on disclosure and appropriate reporting, as well as educational support regarding clinical trials and other matters.

More information can be found at www.ausbiotech.org/biotechboards.

Related News

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

CTA granted for CAR-T cell therapy for multiple myeloma

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd